Travere Therapeutics Inc. Common Stock vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.25 (market cap $2.45B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| TVTX | UUUU | |
|---|---|---|
Market Cap | $4.88B | $2.45B |
Volume | 1,668,577 | 7,967,898 |
Sector | Health | Energy |
52-Week High | $67.52 | $27.72 |
52-Week Low | $26.79 | $8.34 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.01B | $2.19B |
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →